Key points are not available for this paper at this time.
In recent years, the use of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) therapy has significantly increased. Gender differences are poorly studied. Methods: A retrospective review was conducted on 244 patients admitted to the Cardiac ICU who were managed with peripheral VA-ECMO at a tertiary care center between January 2018 and September 2022. The study focused on risk factors associated with ECMO death (defined as dieing on VA-ECMO or within 24 hours of decannulation) using multivariate logistic regression analysis. Additionally, Kaplan Meier analysis assessed 30-day mortality in these patients. Results: Among the 244 patients receiving VA-ECMO, 70 were female (28.7%). De-cannulation rates were numerically higher for females (57.1%) compared to males (43.1%), p=0.051. Both genders had a median VA-ECMOsupportduration of 4.0 days (p=0.855). The median hospital length of stay was also comparable between genders at 10.5 days (p=0.68). No significant differences were found in inpatient death rates, which were high at 70.0% for both groups (p=0.706), or in 1-year survival rates, with females at 15.7% and males at 24.7%, p=0.195. Indications for ECMO were different between the two groups, with a higher prevalence of valvular disease and procedural complications in females, and higher rates of acute myocardial infarction related shock in males (p=0.002). Conclusions: In our single center cohort, indications for VA-ECMO varied significantly between female and male patients, despite similar baseline demographics, while overall outcomes were similar between the two groups. B. B. Basir: Chiesi: Consulting; Abiomed: Consulting; Boston Scientific Corp.: Consulting; Zoll: Consulting; Saranas: Consulting; J. Cowger: Abbott: Consulting; Medtronic: Consulting; CH Biomedical Procyrion: Consulting; Bioventrix: Consulting; CorWave: Consulting; R. Ellauzi, P. Kochhar, R. A. Fadel, S. Willner, Nothing to disclose.
Ellauzi et al. (Wed,) studied this question.